Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects.

Abstract:

OBJECTIVES:Endothelial progenitor cells (EPCs) have been shown to participate in the process of vascular repair, thus playing a protective role against cardiovascular disease (CVD). It is known that atherosclerotic risk factors could affect EPC number and function. Advanced glycation end products (AGEs) contribute to the pathogenesis of atherosclerosis as well. However, as far as we know, there is no report to show the relationship between serum AGE levels and circulating EPCs in humans. Therefore, in this study, we investigated whether serum level of AGEs was associated with EPC number and functions in apparently healthy subjects, independent of traditional cardiovascular risk factors. RESEARCH DESIGN AND METHODS:Apparently healthy volunteers (34.6 ± 6.9 years old, 40 males and 8 females) who were not on any medications underwent a complete history and physical examination, determination of blood chemistries, including AGEs, and number, differentiation and migratory activity of circulating EPCs. RESULTS:Serum AGEs levels were 9.20 ± 1.85 U/mL. Multiple stepwise regression analysis revealed that serum levels of AGEs and smoking were independently correlated with reduced number of EPCs. Further, female, AGEs, and reduced HDL-cholesterol levels were independently associated with impaired migratory activity of circulating EPCs. CONCLUSIONS:This study demonstrated for the first time that the serum level of AGEs was one of the independent correlates of decreased cell number and impaired migratory activity of circulating EPCs in apparently healthy subjects. Our present observations suggest that even in young healthy subjects, serum level of AGEs may be a biomarker that could predict the progression of atherosclerosis and future cardiovascular events.

journal_name

Cardiovasc Ther

authors

Ueda S,Yamagishi S,Matsui T,Noda Y,Ueda S,Jinnouchi Y,Sasaki K,Takeuchi M,Imaizumi T

doi

10.1111/j.1755-5922.2011.00264.x

subject

Has Abstract

pub_date

2012-08-01 00:00:00

pages

249-54

issue

4

eissn

1755-5914

issn

1755-5922

journal_volume

30

pub_type

杂志文章
  • Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.

    abstract:INTRODUCTION:The effectiveness of statin pretreatment in reducing the incidence of contrast-induced nephropathy (CIN) has been examined in some observational and randomized studies, yielding controversial results. AIM:This study sought to evaluate the role of atorvastatin in prevention of CIN in diabetic patients with...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/1755-5922.12108

    authors: Shehata M,Hamza M

    更新日期:2015-04-01 00:00:00

  • Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.

    abstract:AIMS:Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited. We aimed to investigate sex-based differences in clinical outcome of those patients. METHODS:In a prosp...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1755-5922.12270

    authors: Xanthopoulou I,Davlouros P,Deftereos S,Hamilos M,Sitafidis G,Kanakakis I,Vavouranakis M,Goudevenos J,Lekakis J,Alexopoulos D

    更新日期:2017-08-01 00:00:00

  • Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.

    abstract::Accelerated atherosclerosis and microvascular complications are the leading causes of coronary heart disease, stroke, blindness, and end-stage renal failure, which could account for disabilities and high mortality rates in patients with diabetes. Recent clinical studies have substantiated the concept of "hyperglycemic...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1527-3466.2007.00038.x

    authors: Yamagishi S,Nakamura K,Matsui T,Ueda S,Noda Y,Imaizumi T

    更新日期:2008-04-01 00:00:00

  • Hemodynamic Effects, Safety, and Feasibility of Intravenous Esmolol Infusion During Takotsubo Cardiomyopathy With Left Ventricular Outflow Tract Obstruction: Results From A Multicenter Registry.

    abstract:BACKGROUND:Left ventricular outflow tract obstruction (LVOTO) may complicate an episode of Takotsubo cardiomyopathy (TTC), potentially leading to cardiogenic shock. Beta-blockers are considered the most suitable treatment for such complication. AIM OF THE STUDY:The objective of this study was to evaluate the hemodynam...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1755-5922.12182

    authors: Santoro F,Ieva R,Ferraretti A,Fanelli M,Musaico F,Tarantino N,Martino LD,Gennaro LD,Caldarola P,Biase MD,Brunetti ND

    更新日期:2016-06-01 00:00:00

  • A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects.

    abstract:AIMS:We investigated the relative pharmacokinetics, pharmacodynamics, and safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab following injection at three different sites. METHODS:Sixty healthy subjects (39 male, 21 female; age 20-45 years) were randomized to receive a single subcu...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/1755-5922.12093

    authors: Lunven C,Paehler T,Poitiers F,Brunet A,Rey J,Hanotin C,Sasiela WJ

    更新日期:2014-12-01 00:00:00

  • Therapeutic development in cardiac syndrome X: a need to target the underlying pathophysiology.

    abstract::Morbidity of patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriogram) is high with continuing episodes of chest pain and frequent hospital readmissions. Management of this syndrome represents a major challenge for the treating physician. Conventional therapies with antianginal...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2008.00070.x

    authors: Lim TK,Choy AJ,Khan F,Belch JJ,Struthers AD,Lang CC

    更新日期:2009-04-01 00:00:00

  • Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.

    abstract:INTRODUCTION:Real-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. AIMS:To investigate DAPT duration after hospital discharge for ACS in Spain. RESULTS:Data from patients enrolled in the Spani...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/1755-5922.12237

    authors: Bardají A,Leal M,Arrarte V,Garcia-Moll X,Pérez de Isla L,Bueno H

    更新日期:2017-04-01 00:00:00

  • Combating Donor Organ Shortage: Organ Care System Prolonging Organ Storage Time and Improving the Outcome of Heart Transplantations.

    abstract:Introduction:Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the trans...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1155/2019/9482797

    authors: Sunjaya AF,Sunjaya AP

    更新日期:2019-04-01 00:00:00

  • miR-30c Mediates Upregulation of Cdc42 and Pak1 in Diabetic Cardiomyopathy.

    abstract:AIM:Cardiac hypertrophy and myocardial fibrosis significantly contribute to the pathogenesis of diabetic cardiomyopathy (DCM). Altered expression of several genes and their regulation by microRNAs has been reported in hypertrophied failing hearts. This study aims to examine the role of Cdc42, Pak1, and miR-30c in the p...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12113

    authors: Raut SK,Kumar A,Singh GB,Nahar U,Sharma V,Mittal A,Sharma R,Khullar M

    更新日期:2015-06-01 00:00:00

  • Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: a case series.

    abstract:BACKGROUND:Levosimendan is a noncatecholamine inotrope that does not increase oxygen consumption, utilized for the treatment for acute heart failure with left ventricular (LV) systolic dysfunction. Its use in takotsubo cardiomyopathy (TTC), a disease that contraindicates the use of catecholamine inotropes, is not well ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12047

    authors: Santoro F,Ieva R,Ferraretti A,Ienco V,Carpagnano G,Lodispoto M,Di Biase L,Di Biase M,Brunetti ND

    更新日期:2013-12-01 00:00:00

  • Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

    abstract::Atrial fibrillation (AF) is the most common sustained cardiac rhythm disturbance found in clinical practice, increasing in prevalence with age. AF is often associated with structural heart disease, although a significant proportion has no detectable heart disease. In the last 2 decades, there has been an increase of 6...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00216.x

    authors: Escobar C,Barrios V,Jimenez D

    更新日期:2010-10-01 00:00:00

  • Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance.

    abstract::The genetic causes of cholesterol metabolism disorders usually lead to premature atherosclerosis. The most well recognized genetically caused hypercholesterolemia is familial hypercholesterolemia. Although the disease is well known, as the discovery of low-density lipoprotein receptor, the classical treatment with lip...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/1755-5922.12105

    authors: Kolovou G,Vasiliadis I,Gontoras N,Kolovou V,Hatzigeorgiou G

    更新日期:2015-04-01 00:00:00

  • Cell-based therapy for chronic ischemic heart disease--a clinical perspective.

    abstract::In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Becau...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00214.x

    authors: Perin EC,Silva GV

    更新日期:2011-06-01 00:00:00

  • TREK-1 K(+) channels in the cardiovascular system: their significance and potential as a therapeutic target.

    abstract::Potassium (K(+) ) channels are important in cardiovascular disease both as drug targets and as a cause of underlying pathology. Voltage-dependent K(+) (K(V) ) channels are inhibited by the class III antiarrhythmic agents. Certain vasodilators work by opening K(+) channels in vascular smooth muscle cells (VSMCs), and...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00227.x

    authors: Goonetilleke L,Quayle J

    更新日期:2012-02-01 00:00:00

  • The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.

    abstract:AIM:Data evaluating the complications of pulmonary vein isolation (PVI) using second-generation cryoballoons (CB) related to different anticoagulation regimes are limited. This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the ...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12178

    authors: Koektuerk B,Turan CH,Yorgun H,Keskin K,Schoett M,Dahmen A,Gorr E,Yang A,Hoppe C,Horlitz M,Turan RG

    更新日期:2016-06-01 00:00:00

  • Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.

    abstract:INTRODUCTION:Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. AIMS:We use observational long-term data on PA...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12281

    authors: Ascha M,Zhou X,Rao Y,Minai OA,Tonelli AR

    更新日期:2017-10-01 00:00:00

  • New Clinical Classification for Ventricular Free Wall Rupture following Acute Myocardial Infarction.

    abstract::Ventricular free wall rupture (FWR) is a catastrophic complication after acute myocardial infarction (AMI). However, patients with FWR die of cardiac tamponade secondary to intrapericardial hemorrhage that can be treated if properly diagnosed. Unfortunately, FWR was still not diagnosed and classified quickly and accur...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1155/2021/1716546

    authors: Gong W,Nie S

    更新日期:2021-01-02 00:00:00

  • Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.

    abstract::Sex-specific differences have been definitively demonstrated in cardiovascular (CV) diseases. These differences can also impact on the effects of CV therapies. Female sex is recognized as an independent predictor of thromboembolic risk, particularly in older patients. Most of strokes are due to atrial fibrillation (AF...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1155/2020/1743927

    authors: Gallù M,Marrone G,Legramante JM,De Lorenzo A,Di Daniele N,Noce A

    更新日期:2020-06-18 00:00:00

  • Remote physiological ischemic training promotes coronary angiogenesis via molecular and cellular mobilization after myocardial ischemia.

    abstract:AIM:This study was designed to explore the mechanism of physiological ischemic training (PIT) on remote limbs, with a special focus on the potential role of endothelial progenitor cells (EPCs), vascular endothelial growth factor (VEGF), and nitric oxide (NO) in local ischemic myocardium. METHOD:Myocardial ischemia (MI...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12257

    authors: Zheng Y,Xiao M,Li L,Li J,Reinhardt JD,Lu X

    更新日期:2017-06-01 00:00:00

  • Aspirin resistance and compliance with therapy.

    abstract:INTRODUCTION:Aspirin resistance is associated with increased cardiovascular risk in aspirin-treated patients. Poor compliance may explain many cases of "resistance," yet few clinical studies have used objective measurement of therapy compliance. We did so in a case-controlled study. METHODS:We enrolled patients within...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1755-5922.2010.00188.x

    authors: Dawson J,Quinn T,Rafferty M,Higgins P,Ray G,Lees KR,Walters MR

    更新日期:2011-10-01 00:00:00

  • Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.

    abstract::Clopidogrel is an inhibitor of the ADP receptor P2Y12 and platelet aggregation. It is widely used for the management of atherothrombotic disease in patients who have experienced severe vascular events such as stroke or myocardial infarction or with peripheral artery disease. However, some patients show "resistance" to...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2010.00202.x

    authors: Uchiyama S

    更新日期:2011-12-01 00:00:00

  • Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia.

    abstract::The mitochondrial F1F0 ATP synthase is responsible for the majority of ATP production in mammals and does this through a rotary catalytic mechanism. Studies show that the F1F0 ATP synthase can switch to an ATP hydrolase, and this occurs under conditions seen during myocardial ischemia. This ATP hydrolysis causes wasti...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1755-5922.2008.00065.x

    authors: Grover GJ,Malm J

    更新日期:2008-01-01 00:00:00

  • Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.

    abstract::Cilnidipine is a unique Ca(2+) channel blocker with an inhibitory action on the sympathetic N-type Ca(2+) channels, which is used for patients with hypertension in Japan. Cilnidipine has been clarified to exert antisympathetic actions in various examinations from cell to human levels, in contrast to classical Ca(2+) c...

    journal_title:Cardiovascular therapeutics

    pub_type: 历史文章,杂志文章,评审

    doi:10.1111/j.1755-5922.2009.00079.x

    authors: Takahara A

    更新日期:2009-07-01 00:00:00

  • Long Noncoding RNA TUG1 Promotes the Function in ox-LDL-Treated HA-VSMCs via miR-141-3p/ROR2 Axis.

    abstract:Background:Atherosclerosis (AS) is a common severe disease around the world. The merging paper reported that long noncoding RNAs (lncRNAs) took part in diversified pathological processes of AS, although the mechanism remains unknown. This study is aimed at uncovering the profile of lncRNA taurine-upregulated gene 1 (TU...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1155/2020/6758934

    authors: Tang Y,Hu J,Zhong Z,Liu Y,Wang Y

    更新日期:2020-05-29 00:00:00

  • Influence of feeding and intracoronary dose on insulin-mediated relative akt phosphorylation in the porcine myocardium.

    abstract:AIMS:Insulin promotes Akt-dependent prosurvival signaling and reduces experimental ischemia reperfusion injury, but its clinical impact has been limited. Further understanding of the interplay between insulin and Akt in the myocardium of relevant large animal models is needed. We aimed to investigate (1) Akt phosphoryl...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12046

    authors: Slettom G,Jonassen AK,Breivik L,Seifert R,Nordrehaug JE

    更新日期:2013-12-01 00:00:00

  • Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials.

    abstract:INTRODUCTION:Statins are known to prevent heart failure (HF). However, it is unclear whether statins as class or type (lipophilic or hydrophilic) improve outcomes of established HF. AIMS:The current meta-analysis was performed to compare the treatment effects of lipophilic and hydrophilic statins on inflammation and c...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/1755-5922.12150

    authors: Bonsu KO,Reidpath DD,Kadirvelu A

    更新日期:2015-12-01 00:00:00

  • The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

    abstract::Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long-term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/1755-5922.12083

    authors: Cohen M,Iyer D

    更新日期:2014-10-01 00:00:00

  • Prescribers' practice of assessing arrhythmia risk with QT-prolonging medications.

    abstract:AIMS:This study aimed to assess prescribers' monitoring for arrhythmic risk with QT-prolonging medications (LQT drugs). METHODS:Over a 6-month period, all inpatients under the care of Cardiologists (Cohort A) and General Physicians (Cohort B) at Aberdeen Royal Infirmary who were prescribed drugs with known risk of Tor...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12085

    authors: Choo WK,Turpie D,Milne K,Davidson L,Elofuke P,Whitfield J,Broadhurst P

    更新日期:2014-10-01 00:00:00

  • Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.

    abstract:INTRODUCTION:Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear. AIMS:We sought to evaluate the safety and cl...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12111

    authors: LaRue SJ,Garcia-Cortes R,Nassif ME,Vader JM,Ray S,Ravichandran A,Rasalingham R,Silvestry SC,Ewald GA,Wang IW,Schilling JD

    更新日期:2015-04-01 00:00:00

  • Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.

    abstract:INTRODUCTION:Options for a pharmacological cardioversion (CV) of short-duration atrial fibrillation (AF) in patients with a stable coronary artery disease (CAD) are limited to amiodarone or vernakalant. Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness an...

    journal_title:Cardiovascular therapeutics

    pub_type: 杂志文章

    doi:10.1111/1755-5922.12469

    authors: Farkowski MM,Maciag A,Zurawska M,Kowalik I,Szwed H,Pytkowski M

    更新日期:2018-12-01 00:00:00